Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.
about
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to reninUpdate on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseThe world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system.Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.A genetically clamped renin transgene for the induction of hypertensionProrenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents.A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link?Increased dietary NaCl potentiates the effects of elevated prorenin levels on blood pressure and organ disease.Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio.Cardiorenal syndrome is present in human fetuses with severe, isolated urinary tract malformationsTransgenic models of tolerance and autoimmunity: with special reference to systemic lupus erythematosus.New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin IIRenin inhibitors in diabetes and hypertension: an update.Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign NephrosclerosisHypertension, kidney, and transgenics: a fresh perspective.The Prorenin and (Pro)renin Receptor: New Players in the Brain Renin-Angiotensin System?The (pro)renin receptor. A decade of research: what have we learned?Prorenin anno 2008.Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users.Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.Renin inhibition in the treatment of diabetic kidney disease.Nephrosclerosis: update on a centenarian.The Role of the (Pro)renin Receptor in Hypertensive Disease.Direct inhibition of plasmatic renin activity with aliskiren: a promising but under-investigated therapeutic option for non-diabetic glomerulonephritis.Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.Higher plasma prorenin concentration plays a role in the development of coronary artery diseaseControlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease.A specific binding site for the prorenin propart peptide Arg10-Arg20 does not occur on human endothelial cells.Cardiac remodeling during and after renin-angiotensin system stimulation in Cyp1a1-Ren2 transgenic rats.Serum prorenin levels are not associated with ocular diseases in non-diabetic subjects.Transgenic animal models for the functional analysis of vasoactive peptides.Spotlight on ReninAssociation of (pro)renin receptor gene polymorphisms with lacunar infarction and left ventricular hypertrophy in Japanese women: the Ohasama study
P2860
Q24298747-1319D6D8-3395-4E2D-B0E3-BA88A4E775D1Q28077454-37040CF3-75AC-4DBE-B00C-BCB9DD418D15Q30426517-D849620E-C2AE-49BA-80CD-D934BA450F82Q30452640-3B8A86EB-57EB-4EEF-A3A3-7CD899EDF9D8Q30453336-48AFC8D2-2183-49A4-A816-CE5263319EFEQ31151042-DF71F8D7-7E4C-436E-BDF3-87E2BD245880Q33625889-CDDC4C9E-F200-4BE3-B274-34E78F7CFD1DQ33942556-7F941F13-195A-4CFA-BCAA-E7C429E98B90Q34032089-538D98FA-7DA8-4AD0-A478-DD53698DCC96Q34590536-D0FA5492-2FBE-4616-9BB1-A30E4DC626F1Q34744358-5DCC6AEB-DDA9-4DD0-A492-53ED17445228Q35045906-4D71D29D-079F-451A-9C07-14F4068771D5Q35109349-AE410A9A-7799-426D-811F-5307C4CABC56Q35728190-12A9A9BC-8FBC-4079-BD66-C2D35826DA79Q35904061-481F12F9-018B-4013-96B7-256C1372DDCBQ36443015-8B9250C2-BB88-4DF7-8ECD-1CA6B872427AQ36506655-62E5C6DF-A314-4DC7-949A-97F4ACDE1B1CQ36557476-8B875667-DD69-4220-BA69-E63AA050B61CQ36642799-175ABF88-4BA0-47ED-9EFB-97FDB22867F8Q36924964-542242F2-59A6-45FD-BC1D-9A59B8F0B025Q36956046-086F043A-35BA-4699-A836-20F18305B991Q37155210-763CEC87-0ADB-4195-B5FF-DFD8C30CD22BQ37993917-9BCAA23D-29CC-4B93-8136-D0136FD324C3Q38075571-AD5E41EF-B3A1-45A4-BF35-808F4B0024BCQ38285618-10955558-6753-4A29-A249-6AA114655623Q38428278-0EE72BDF-45B5-45AF-A755-06F980F54F81Q38599694-F0E1B95D-118D-4B20-B574-D46EE1112A34Q40176844-8E79F8AE-88D3-45CA-BFBA-9EA020F8D405Q41127165-523820A9-ECA6-4738-8F77-4CF53A247C92Q43670943-4565DE56-756A-40B5-B01F-2588F2391BC1Q43856359-CD0F5BD1-F505-410F-8654-67294E942833Q46533413-C26A5980-B044-42CF-B267-31C7E1CCC8A9Q51314073-CB756440-25AB-4895-AE9B-16B06B198BF9Q52981348-805C67BF-AE57-4E8A-932A-A5A0E7599688Q56963450-B85714E4-D969-47CE-B23C-B48B15111A08Q58363314-E527B8C7-4CB4-4698-98FA-05821D86BB24
P2860
Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Vascular damage without hypert ...... enin exclusively in the liver.
@en
Vascular damage without hypert ...... enin exclusively in the liver.
@nl
type
label
Vascular damage without hypert ...... enin exclusively in the liver.
@en
Vascular damage without hypert ...... enin exclusively in the liver.
@nl
prefLabel
Vascular damage without hypert ...... enin exclusively in the liver.
@en
Vascular damage without hypert ...... enin exclusively in the liver.
@nl
P2093
P2860
P356
P1476
Vascular damage without hypert ...... enin exclusively in the liver.
@en
P2093
P2860
P304
P356
10.1172/JCI119000
P407
P577
1996-11-01T00:00:00Z